Summary
Colorectal carcinoma cells have recently been shown to express Fas ligand (FasL). This ligand could allow the tumour cells to evade activated tumour-infiltrating lymphocytes (TILs) by inducing their apoptosis and would thus promote tumour survival and possibly metastasis formation. To test this hypothesis in vivo we analysed the expression of FasL mRNA and protein in paired tissue samples of normal colonic mucosa (N), primary colorectal carcinomas (T) and their metastases (M) from a total of 21 patients by four different methods. Additionally, the presence and activation status of infiltrating lymphocytes, which might contribute to the total amount of FasL in the tissue, was determined by semiquantitative reverse transcription–polymerase chain reaction (RT–PCR) in the same samples. The frequency of FasL detection was 30–40% in T and was 60–100% in M, depending on the sensitivity of the method. Simultaneously, the amount of CD25 mRNA, used as a measure of the number of activated TILs, was in 90% of patients lower in M than in T. The increased frequency of FasL detection in liver metastases was therefore not due to the presence of activated TILs. We conclude that metastasizing subpopulations of colorectal tumour cells express FasL more frequently than the primary carcinomas and may be able to eliminate activated TILs in vivo via Fas/FasL-induced apoptosis or other hitherto unknown mechanisms.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ambe, K., Mori, M. & Enjoji, M. (1989). S-100 protein positive dendritic cells in colorectal adenocarcinomas. Cancer 63: 496–503.
Arai, H., Gordon, D., Nabel, E. G. & Nabel, G. J. (1997). Gene transfer of Fas ligand induces tumour regression in vivo. Proc Natl Acad Sci USA 94: 13862–13867.
Barth, R. J., Camp, B. J., Martuscello, T. A., Dain, B. J. & Memoli, V. A. (1996). The cytokine microenvironment of human colon carcinoma. Cancer 78: 1168–1178.
Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A. & Duke, R. C. (1995). A role of CD95 ligand in preventing graft rejection. Nature 377: 630–632.
Brunner, T. H., Mogli, R. J., LaFace, D., Yoo, N. J., Mahboubi, A., Echeverri, F., Martin, S. J., Force, W. R., Lynch, D. H., Ware, C. F. & Green, D. R. (1995). Cell autonomous Fas/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373: 441–444.
De Maria, R., Boirivant, M., Cifone, M. G., Roncaioli, P., Hahne, M., Tschopp, J., Pallone, F., Santoni, A. & Testi, R. (1996). Functional expression of Fas and Fas Ligand on human gut lamina propria T lymphocytes. J Clin Invest 97: 316–322.
Dhein, J., Walczak, H., Bäumler, C., Debatin, K. M. & Krammer, P. H. (1995). Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373: 438–441.
Ehl, S., Hoffmann-Rohrer, U., Nagata, S., Hengartner, H. & Zinkernagel, R. (1996). Different susceptibility of cytotoxic T-cells to CD95 ligand-mediated cell death after activation in vitro vs in vivo. J Immunol 156: 2357–2360.
Foss, H. D., Demel, G., Anagnostopoulos, I., Aranjo, I., Hummel, M. & Stein, H. (1997). Uniform expression of cytotoxic molecules in anaplastic large cell lymphoma of Null/T-cell phenotype and in cell lines derived from anaplastic large cell lymphomas. Pathobiology 65: 83–90.
French, L. E. & Tschopp, J. (1996). Constitutive Fas Ligand expression in several non-lymphoid mouse tissues and implications for immune-protection and cell turnover. Behring Inst Mitt 97: 156–160.
French, L. E., Hahne, M., Vicard, I., Radlgruber, G., Zanone, R., Becker, K., Möller, C. & Tschopp, J. (1996). Fas and Fas ligand in embryos and adult mice: ligand expression in several immune privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 133: 335–343.
Galle, P. R., Hofmann, W. J., Walczak, H., Schaller, H., Otto, G., Stremmel, W., Krammer, P. H. & Runkel, L. (1995). Involvement of the CD95 receptor and ligand in liver damage. J Exp Med 182: 1223–1230.
Griffith, T. S., Brunner, T. H., Fletcher, S. M., Green, D. R. & Ferguson, T. A. (1995). Fas ligand induced apoptosis as a mechanism of immune privilege. Science 270: 1189–1192.
Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J. C. & Tschopp, J. (1996). Melanoma cell expression of Fas(Apo-1/CD95) Ligand: implications for tumour immune escape. Science 274: 1363–1366.
James-Yarish, M., Bradley, W. G., Emmanuel, P. J., Good, R. A. & Day, N. K. (1994). Detection of cell specific cluster determinant expression by reverse transcription polymerase chain reaction. J Immunol Meth 169: 73–82.
Kang, S. M., Schneider, D. B., Lin, Z., Hanahan, D., Dichek, D. A., Stock, P. G. & Baekkeskov, S. (1997). Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med 3: 738–743.
Kemmner, W., Schlag, P. & Brossmer, R. (1987). A rapid and simple procedure for dissociation of tumour tissue from the human colon. J Cancer Res Clin Oncol 113: 400–401.
Möller, P., Koretz, K., Leihäuser, F., Brüderlein, S., Henne, C., Quentmeier, A. & Krammer, P. H. (1994). Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 57: 371–377.
Mulder, W. M. C., Bloemena, E., Stukart, M. J., Kummer, J. A., Wagstaff, R. J. & Scheper, R. J. (1997). T-cell receptor-zetta and granzyme B expression in mononuclear cell infiltrates in normal colonic mucosa and colon carcinoma. Gut 40: 113–119.
Nagata, S. & Golstein, P. (1995). The Fas death factor. Science 267: 1449–1456.
Niehans, G. A., Brunner, T., Frizelle, S. P., Liston, J. C., Salerno, T., Knapp, D. J., Green, D. R. & Kratzke, R. A. (1997). Human lung carcinomas express Fas-ligand. Cancer Res 57: 1007–1012.
O’Connell, J., Sullivan, G. C. & Collins, J. K. (1996). The Fas counterattack: Fas-mediated T-cell killing by colon cancer cells expressing Fas-Ligand. J Exp Med 184: 1075–1082.
Oshimi, Y., Oda, S., Honda, Y., Nagata, S. & Miyazaki, S. (1996). Involvement of Fas Ligand and Fas mediated pathway in the cytotoxicity of human natural killer cells. J Immunol 157: 2909–2915.
Østenstad, B., Lea, T., Schlichting, E. & Harboe, M. (1994). Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45R0 molecule, showing a primed population of lymphocytes in the tumour area. Gut 35: 382–387.
Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY
Seino, K. I., Kayagaki, N., Okumura, K. & Yagita, H. (1997). Antitumour effect of locally produced CD95 ligand. Nature Med 3: 165–170.
Shimizu, Y., Watanabe, A. & Whiteside, T. L. (1992). Memory T-lymphocytes are the main population of tumour infiltrating lymphocytes obtained from human primary liver tumours. J Hepatol 16: 197–202.
Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, J. & Takahashi, H. (1997). Expression of Fas-ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 94: 6420–6425.
Strand, S., Hofmann, W. J., Hug, H., Müller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H. & Galle, P. R. (1996). Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumour cells – a mechanism of immune evasion? Nature Med 2: 1361–1366.
Strasser, A. & O’Connor, L. (1998). Fas ligand – caught between scylla and charybdis. Nature Med 4: 21–23.
Suda, T., Takahashi, T., Golstein, P. & Nagata, S. (1993). Molecular cloning and expression of FasL, a novel member of the tumor necrosis factor family. Cell 75: 1169–1178.
Walker, P. R., Saas, P. & Dietrich, P. Y. (1997). Role of FasL in immune escape – the tumour cell strikes back. J Immunol 158: 4521–4524.
Zeytun, A., Hassuneh, M., Nagarkatti, M. & Nagarkatti, P. S. (1997). Fas–Fas ligand-based interactions between tumour cells and tumour-specific cytotoxic T lymphocytes: a lethal two-way street. Blood 90: 1952–1959.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Mann, B., Gratchev, A., Böhm, C. et al. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 79, 1262–1269 (1999). https://doi.org/10.1038/sj.bjc.6690202
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690202
Keywords
This article is cited by
-
Retinoic acid morpholine amide (RAMA) inhibits expression of Fas ligand through EP1 receptor in colon cancer cells
Tumor Biology (2016)
-
The role of CD95 and CD95 ligand in cancer
Cell Death & Differentiation (2015)
-
Tissue Expression of the Proteins Fas and Fas Ligand in Colorectal Cancer and Liver Metastases
Journal of Gastrointestinal Cancer (2012)
-
Expression of TNF-related apoptosis-inducing ligand (TRAIL) in keratinocytes mediates apoptotic cell death in allogenic T cells
Annals of Surgical Innovation and Research (2009)
-
Serum sFas and Tumor Tissue FasL Negatively Correlated with Survival in Egyptian Patients Suffering from Breast Ductal Carcinoma
Pathology & Oncology Research (2009)
